588P Androgen changes after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial

Autor: Kvorning Ternov, K., Sønksen, J., Fode, M., Lindberg, H., Kistorp, C., Bisbjerg, R., Faber, J., Palapattu, G., Østergren, P.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S637-S637

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A0522 - Changes in pituitary–gonadal hormones after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial.

Autor: Kvorning Ternov, K. (AUTHOR), Sønksen, J. (AUTHOR), Fode, M. (AUTHOR), Lindberg, H. (AUTHOR), Kistorp, C. (AUTHOR), Bisbjerg, R. (AUTHOR), Faber, J. (AUTHOR), Palapattu, G. (AUTHOR), Østergren, P.B. (AUTHOR)

Publikováno v: European Urology. 2022 Supplement 1, Vol. 81, pS786-S787. 2p.

Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.

Autor: Kvorning Ternov K; Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark klara.kvorning.ternov@regionh.dk., Sønksen J; Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark., Fode M; Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark., Lindberg H; Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark., Kistorp CM; Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Bisbjerg R; Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark., Palapattu G; Department of Urology, Michigan Medicine, Ann Arbor, Michigan, USA., Østergren PB; Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark.

Publikováno v: BMJ open [BMJ Open] 2019 Sep 11; Vol. 9 (9), pp. e030218. Date of Electronic Publication: 2019 Sep 11.